FASN and breast cancer: In summary, our data demonstrate that the inhibition of HER2 kinase activity by lapatinib results in decreased FASN tyrosine phosphorylation and reduced FASN enzymatic activity, which further downregulates HER2 signaling and results in suppressed breast cancer cell invasion.